“We’re going to review CHEK2-related management guidelines, hereditary cancer implications for males and their families…and the importance of cascade testing,” says Veda N. Giri, MD.
In this video, Veda N. Giri, MD, previews the upcoming ENGAGEMENT study virtual genetics board’s February case discussion (https://www.prostategenetics.com/engagement). Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.
2 Commerce Drive
Cranbury, NJ 08512